1 insider has bought $84k of Adagene Inc. shares across 1 disclosed dealing since August 2026.
| Aug 4, 2026 | Luo Peter — Chief Executive Officer | $83,746 |
Adagene Inc. is classed as health care. By value disclosed, that ranks 34th of the 44 health care companies where insiders bought in the last twelve months.
Companies with a comparable amount of disclosed buying: DarioHealth Corp. · AUNA S.A. · BlossomHill Therapeutics, Inc. · Guardant Health, Inc. · CVRx, Inc. · IMMUCELL CORP
See also the biggest buys, cluster buying and the most-active companies.
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
Every row is a public regulatory disclosure — a Form 4 filing with the SEC — collected within minutes of being published. We don’t take company submissions and we don’t edit the numbers; the only thing we add is the rating and the reasoning behind it.
Sometimes. A insider buying with their own money is one of the few honest signals in the market, but plenty of purchases are routine — small top-ups, scheme allocations, or a well-paid executive rounding out a holding. That’s what our six-point check is for: it separates the conviction buys from the housekeeping, and shows you which is which.
The pipeline runs every 15 minutes through the trading day, so a new disclosure appears here shortly after it’s filed. Company stats refresh daily.
Yes — that’s what the app is for. Follow Adagene Inc. and you’ll get a push the moment a insider files, with the full analysis attached, plus alerts if the price moves after a buy you’re following.
No. ddbx rates the conviction behind insider buys and shows the reasoning. It’s information, never a recommendation, and never a guarantee. What you do with it is your call.